Laissez-Faire Founders Fund Sets Sights On Health Care
This article was originally published in Start Up
Armed with an investment manifesto and aiming to place big bets on high-risk, high-reward start-ups led by extraordinary minds, San Francisco-based Founders Fund has recently closed a $625 million fund and is now testing its thesis on life sciences and health care information technology start-ups.
You may also be interested in...
As traditional venture-like returns are harder to generate from drug development and medtech plays, some frustrated VCs see new opportunities in health care information technology, an area many have traditionally avoided.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.